Peter Reiss

Author PubWeight™ 339.75‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002 16.56
2 Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007 12.93
3 Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003 12.23
4 Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008 11.72
5 Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010 9.26
6 Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006 9.21
7 Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012 8.94
8 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008 8.73
9 Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008 5.94
10 Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS 2003 5.61
11 Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005 5.20
12 Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007 4.31
13 Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008 4.10
14 Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004 3.59
15 Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010 3.47
16 Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010 3.30
17 CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 2007 3.18
18 Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis 2013 3.04
19 Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010 2.98
20 Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010 2.85
21 Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr 2014 2.79
22 Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 2003 2.78
23 Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010 2.70
24 Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010 2.59
25 Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007 2.51
26 Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 2013 2.49
27 Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005 2.45
28 HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008 2.27
29 Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. AIDS 2013 2.11
30 Chronic renal failure among HIV-1-infected patients. AIDS 2007 2.07
31 Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation 2009 2.01
32 The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 2005 1.97
33 Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009 1.96
34 Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 2009 1.90
35 Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004 1.89
36 Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 2009 1.86
37 Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther 2008 1.83
38 Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue. Arterioscler Thromb Vasc Biol 2005 1.75
39 HIV-1 infection and cognitive impairment in the cART era: a review. AIDS 2011 1.72
40 Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002 1.70
41 Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med 2014 1.69
42 An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS 2013 1.64
43 The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther 2002 1.61
44 The restoration potential of the Mesopotamian marshes of Iraq. Science 2005 1.60
45 The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology 2011 1.59
46 Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis 2014 1.59
47 Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy. J Acquir Immune Defic Syndr 2011 1.58
48 Factors affecting transmission of mucosal human papillomavirus. Lancet Infect Dis 2010 1.56
49 Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clin Infect Dis 2010 1.54
50 Effects of antiretroviral therapy on semen quality. AIDS 2008 1.54
51 CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med 2012 1.54
52 Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005 1.52
53 Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS 2006 1.52
54 Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS 2015 1.44
55 A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003 1.43
56 Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003 1.41
57 One-pot synthesis of highly luminescent InP/ZnS nanocrystals without precursor injection. J Am Chem Soc 2008 1.39
58 Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003 1.34
59 Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Euro Surveill 2015 1.29
60 Prospects of nanoscience with nanocrystals. ACS Nano 2015 1.27
61 First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 2009 1.27
62 Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis 2014 1.25
63 Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation 2008 1.24
64 Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2011 1.22
65 Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. J Infect Dis 2009 1.20
66 Immunologic, virologic, and clinical consequences of episodes of transient viremia during suppressive combination antiretroviral therapy. J Acquir Immune Defic Syndr 2008 1.19
67 Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS 2008 1.18
68 Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS 2012 1.16
69 High seroprevalence of HBV and HCV infection in HIV-infected adults in Kigali, Rwanda. PLoS One 2013 1.16
70 Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002 1.15
71 Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. AIDS 2007 1.15
72 Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther 2005 1.14
73 Long-term effectiveness of combination antiretroviral therapy and prevalence of HIV drug resistance in HIV-1-infected children and adolescents in Rwanda. Pediatr Infect Dis J 2014 1.12
74 Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med 2010 1.12
75 Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. J Acquir Immune Defic Syndr 2009 1.11
76 Triple HIV-1 infection. N Engl J Med 2005 1.09
77 Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS 2002 1.07
78 High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010 1.07
79 Living situation affects adherence to combination antiretroviral therapy in HIV-infected adolescents in Rwanda: a qualitative study. PLoS One 2013 1.06
80 Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease. J Infect Dis 2005 1.06
81 Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. J Acquir Immune Defic Syndr 2009 1.04
82 Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. J Acquir Immune Defic Syndr 2009 1.04
83 Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS 2014 1.03
84 Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 2005 1.03
85 Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. J Int AIDS Soc 2012 1.03
86 High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS 2010 1.02
87 Effect of poly(ethylene glycol) length on the in vivo behavior of coated quantum dots. Langmuir 2009 1.01
88 A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function. Clin Nephrol 2012 1.00
89 HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Antivir Ther 2010 1.00
90 Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS 2003 0.99
91 Lipid profiles associated with antiretroviral drug choices. Curr Opin Infect Dis 2003 0.99
92 Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir Ther 2004 0.99
93 Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. BMC Infect Dis 2013 0.98
94 HIV-1 sequence evolution in vivo after superinfection with three viral strains. Retrovirology 2007 0.98
95 Increased carotid intima-media thickness in HIV patients treated with protease inhibitors as compared to non-nucleoside reverse transcriptase inhibitors. Atherosclerosis 2008 0.98
96 Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. Clin Infect Dis 2012 0.98
97 Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS 2013 0.98
98 Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study. Clin Infect Dis 2008 0.98
99 Chelating ligands for nanocrystals' surface functionalization. J Am Chem Soc 2004 0.97
100 Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study. J Clin Virol 2003 0.96
101 Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. AIDS 2004 0.96
102 Impact of nevirapine on lipid metabolism. J Acquir Immune Defic Syndr 2003 0.96
103 Multivariate normative comparison, a novel method for more reliably detecting cognitive impairment in HIV infection. AIDS 2015 0.96
104 Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. AIDS 2011 0.96
105 Episodes of HIV viremia and the risk of non-AIDS diseases in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr 2012 0.96
106 HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls. AIDS 2016 0.95
107 Cutting edge: Rapid recovery of NKT cells upon institution of highly active antiretroviral therapy for HIV-1 infection. J Immunol 2006 0.94
108 Associations between immune depression and cardiovascular events in HIV infection. AIDS 2013 0.94
109 Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care 2008 0.94
110 Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther 2007 0.93
111 Unraveling the core-shell structure of ligand-capped Sn/SnOx nanoparticles by surface-enhanced nuclear magnetic resonance, Mössbauer, and X-ray absorption spectroscopies. ACS Nano 2014 0.93
112 Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother 2003 0.93
113 Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol 2009 0.92
114 Antiretroviral therapy drug adherence in Rwanda: perspectives from patients and healthcare workers using a mixed-methods approach. AIDS Care 2013 0.92
115 Prediction of residual time to AIDS and death based on markers and cofactors. J Acquir Immune Defic Syndr 2003 0.92
116 Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS 2011 0.91
117 Abacavir and cardiovascular risk. Curr Opin Infect Dis 2010 0.91
118 Infection with HIV-1 induces a decrease in mtDNA. J Infect Dis 2005 0.91
119 Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? J Hepatol 2013 0.90
120 Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study. J Clin Endocrinol Metab 2013 0.90
121 Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda. Pediatr Infect Dis J 2013 0.90
122 Internal structure of InP/ZnS nanocrystals unraveled by high-resolution soft X-ray photoelectron spectroscopy. ACS Nano 2010 0.89
123 Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS 2011 0.89
124 Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. J Acquir Immune Defic Syndr 2008 0.89
125 The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters. AIDS 2010 0.89
126 Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study. Antivir Ther 2004 0.89
127 Clinical spectrum, risk factors and outcome of immune reconstitution inflammatory syndrome in patients with tuberculosis-HIV coinfection. Antivir Ther 2012 0.88
128 Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen. Ther Drug Monit 2007 0.88
129 Highly active antiretroviral therapy-induced lipodystrophy has minor effects on human immunodeficiency virus-induced changes in lipolysis, but normalizes resting energy expenditure. J Clin Endocrinol Metab 2002 0.87
130 Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. PLoS One 2009 0.87
131 Is the male genital tract really a sanctuary site for HIV? Arguments that it is not. AIDS 2004 0.86
132 Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. Antivir Ther 2010 0.86
133 Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study. J Acquir Immune Defic Syndr 2015 0.86
134 Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy. AIDS 2016 0.85
135 Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opin Drug Saf 2005 0.85
136 Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment. Antivir Ther 2010 0.85
137 Low bone mineral density, regardless of HIV status, in men who have sex with men. J Infect Dis 2012 0.85
138 Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. Clin Infect Dis 2013 0.85
139 Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy. J Infect Dis 2005 0.85
140 Amine-induced growth of an In2O3 shell on colloidal InP nanocrystals. Chem Commun (Camb) 2007 0.85
141 Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. AIDS 2012 0.85
142 How bad is HAART for the HEART? AIDS 2003 0.84
143 Highly luminescent Cd1-xZnxSe/ZnS core/shell nanocrystals emitting in the blue-green spectral range. Small 2007 0.84
144 Viral replication under combination antiretroviral therapy: a comparison of four different regimens. J Acquir Immune Defic Syndr 2002 0.84
145 Semen quality remains stable during 96 weeks of untreated human immunodeficiency virus-1 infection. Fertil Steril 2007 0.84
146 Effect of surface ligands on the optical properties of aqueous soluble CdTe quantum dots. Nanoscale Res Lett 2012 0.83
147 Local and systemic increase in lipid peroxidation after moderate experimental traumatic brain injury. J Neurochem 2002 0.83
148 Europium doped In(Zn)P/ZnS colloidal quantum dots. Dalton Trans 2013 0.83
149 Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study. Antivir Ther 2009 0.83
150 Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. J Infect Dis 2006 0.83
151 Cell-permeable Ln(III) chelate-functionalized InP quantum dots as multimodal imaging agents. ACS Nano 2011 0.83
152 Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. Clin Infect Dis 2015 0.83
153 Immune restoration and onset of new AIDS-defining events with combination antiretroviral therapy in HIV type-1-infected immigrants in the Netherlands. Antivir Ther 2010 0.82
154 Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. AIDS 2016 0.82
155 Aqueous phase transfer of InP/ZnS nanocrystals conserving fluorescence and high colloidal stability. ACS Nano 2011 0.82
156 Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? Antivir Ther 2005 0.82
157 Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase. J Virol 2005 0.82
158 Insulin sensitivity in multiple pathways is differently affected during zidovudine/lamivudine-containing compared with NRTI-sparing combination antiretroviral therapy. J Acquir Immune Defic Syndr 2010 0.82
159 White matter structure alterations in HIV-1-infected men with sustained suppression of viraemia on treatment. AIDS 2016 0.82
160 Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosine. AIDS 2016 0.82
161 An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes. J Antimicrob Chemother 2013 0.81
162 A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy. Am J Physiol Endocrinol Metab 2009 0.81
163 Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen. Antivir Ther 2007 0.81
164 Mitochondrial DNA decline in T cells of HIV-1 seroconverters may be dependent on immune activation. J Infect Dis 2007 0.81
165 Drug interactions between statins and antiretroviral agents. Curr Opin HIV AIDS 2008 0.81
166 Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis. Antivir Ther 2011 0.81
167 The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression. Antivir Ther 2012 0.81
168 Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection. AIDS Rev 2010 0.80
169 Atherosclerotic vascular disease in HIV: it is not just antiretroviral therapy that hurts the heart! Curr Opin HIV AIDS 2007 0.80
170 Bone mineral density increases in HIV-infected children treated with long-term combination antiretroviral therapy. Clin Infect Dis 2012 0.80
171 The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. J Antimicrob Chemother 2006 0.80
172 Safety and efficacy of once-daily nevirapine dosing: a multicohort study. Antivir Ther 2009 0.80
173 Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients. J Infect Dis 2007 0.80
174 Size and ligand effects on the electrochemical and spectroelectrochemical responses of CdSe nanocrystals. Phys Chem Chem Phys 2005 0.80
175 Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. Arch Intern Med 2002 0.80
176 Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clin Infect Dis 2016 0.79
177 Common inherited mitochondrial DNA mutations and nucleoside reverse transcriptase inhibitor-induced severe hyperlactataemia in HIV-infected adults: an exploratory study. Antivir Ther 2011 0.79
178 The long-term consequences of antiretroviral therapy: a review. J HIV Ther 2006 0.79
179 Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: the D: A: D study. J Acquir Immune Defic Syndr 2013 0.79
180 Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir. Antivir Ther 2003 0.79
181 Neurometabolite Alterations Associated With Cognitive Performance in Perinatally HIV-Infected Children. Medicine (Baltimore) 2016 0.79
182 The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration. Antivir Ther 2011 0.79
183 Dialysis and renal transplantation in HIV-infected patients: a European survey. J Acquir Immune Defic Syndr 2010 0.79
184 CD4+ cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, sex and calendar time. AIDS 2015 0.78
185 Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice. Atherosclerosis 2009 0.78
186 Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antivir Ther 2006 0.78
187 Compact quantum dot-antibody conjugates for FRET immunoassays with subnanomolar detection limits. Nanoscale 2016 0.78
188 Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA. AIDS 2012 0.78
189 When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study. J Acquir Immune Defic Syndr 2016 0.78
190 Impact of comorbidity and ageing on health-related quality of life in HIV-positive and HIV-negative individuals. AIDS 2017 0.77
191 Synthesis of homogeneous FePt nanoparticles using a nitrile ligand. Small 2008 0.77
192 Sympathetic nervous system function in HIV-associated adipose redistribution syndrome. AIDS 2006 0.77
193 Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. BMC Nephrol 2014 0.77
194 Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection. Expert Opin Drug Saf 2015 0.77
195 Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART. Scand J Infect Dis 2008 0.77
196 Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients. J Clin Endocrinol Metab 2004 0.77
197 Influence of the catalyst type on the growth of carbon nanotubes via methane chemical vapor deposition. J Phys Chem B 2006 0.77
198 Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy. J Infect Dis 2007 0.77
199 Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES). HIV Clin Trials 2007 0.77
200 Surface oxidation of tin chalcogenide nanocrystals revealed by 119Sn-Mössbauer spectroscopy. J Am Chem Soc 2012 0.77
201 White matter hyperintensities in relation to cognition in HIV-infected men with sustained suppressed viral load on combination antiretroviral therapy. AIDS 2016 0.77
202 Luminescence of polyethylene glycol coated CdSeTe/ZnS and InP/ZnS nanoparticles in the presence of copper cations. Chemphyschem 2011 0.77
203 A simple and general route for monofunctionalization of fluorescent and magnetic nanoparticles using peptides. Nanotechnology 2011 0.77
204 Quenching dynamics in CdSe nanoparticles: surface-induced defects upon dilution. ACS Nano 2012 0.77
205 Difference in Aortic Stiffness Between Treated Middle-Aged HIV Type 1-Infected and Uninfected Individuals Largely Explained by Traditional Cardiovascular Risk Factors, With an Additional Contribution of Prior Advanced Immunodeficiency. J Acquir Immune Defic Syndr 2016 0.77
206 Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. AIDS 2004 0.76
207 When to Start Antiretroviral Therapy and What to Start With-- A European Perspective. Curr Infect Dis Rep 2003 0.76
208 Higher subcortical and white matter cerebral blood flow in perinatally HIV-infected children. Medicine (Baltimore) 2017 0.75
209 The art of managing human immunodeficiency virus infection: a balancing act. Clin Infect Dis 2009 0.75
210 HIV and ageing: improving quantity and quality of life. Curr Opin HIV AIDS 2016 0.75
211 Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals. Medicine (Baltimore) 2016 0.75
212 Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals? AIDS 2016 0.75
213 Rational design of the gram-scale synthesis of nearly monodisperse semiconductor nanocrystals. Nanoscale Res Lett 2011 0.75
214 Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis. AIDS 2016 0.75
215 Synthesis and surface chemistry of high quality wurtzite and kesterite Cu2ZnSnS4 nanocrystals using tin(II) 2-ethylhexanoate as a new tin source. Chem Commun (Camb) 2015 0.75
216 Layer-by-layer assembled composite films of side-functionalized poly(3-hexylthiophene) and CdSe nanocrystals: electrochemical, spectroelectrochemical and photovoltaic properties. Phys Chem Chem Phys 2008 0.75
217 Impact of HIV care facility characteristics on the cascade of care in HIV-infected patients in the Netherlands. AIDS 2016 0.75
218 Optimizing the relaxivity of GdIII complexes appended to InP/ZnS quantum dots by linker tuning. Dalton Trans 2013 0.75
219 Mitochondria, HIV infection and its treatment: where do we go from here? Antivir Ther 2005 0.75
220 Research in action: from AIDS to global health to impact. A symposium in recognition of the scientific contributions of Professor Joep Lange. Antivir Ther 2015 0.75
221 High need to switch cART or co-medication with the initiation of DAAs in elderly HIV/HCV co-infected patients. J Acquir Immune Defic Syndr 2017 0.75
222 Correction: Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe. PLoS Biol 2017 0.75
223 Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. AIDS 2016 0.75
224 Epidemiology of ageing with HIV: what can we learn from cohorts? AIDS 2017 0.75
225 Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals. AIDS 2017 0.75
226 Editorial comment. Curr Opin HIV AIDS 2007 0.75
227 Working together to provide generics for health. Antivir Ther 2014 0.75
228 Aqueous synthesis of DNA-Functionalized Near-Infrared AgInS2/ZnS Core/Shell Quantum Dots. ACS Appl Mater Interfaces 2020 0.75
229 Brief Report: High Need to Switch cART or Comedication With the Initiation of DAAs in Elderly HIV/HCV-Coinfected Patients. J Acquir Immune Defic Syndr 2017 0.75
230 Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. AIDS 2017 0.75
231 Cerebral blood flow and cognitive function in HIV-infected men with sustained suppressed viremia on combination antiretroviral therapy. AIDS 2017 0.75
232 Langmuir-Schaeffer monolayers of colloidal nanocrystals for cost-efficient quantum dot light-emitting diodes. Adv Mater 2012 0.75
233 Hypertension in people living with HIV. Curr Opin HIV AIDS 2017 0.75
234 Stable colloidal solutions of high-temperature-annealed L10 FePt nanoparticles. Small 2010 0.75
235 Effect of immediate initiation of antiretroviral treatment in HIV-positive individuals aged 50 years or older. J Acquir Immune Defic Syndr 2017 0.75